This website is intended for UK healthcare professionals only Log in | Register

Editorial articles

November 2022 Br J Cardiol 2022;29:129–31 doi:10.5837/bjc.2022.035

Secondary prevention lipid management following ACS: a missed opportunity?

Zahid Khan, Roby Rakhit

Abstract

Acute coronary syndrome (ACS) is one of the leading causes for morbidity and mortality in the world despite advances in treatment as shown by both short- and long-term studies.1 Studies demonstrate that factors responsible for increased risk of future cardiovascular events are often ignored resulting in increased morbidity and mortality.1,2 Despite the significant reduction of in-hospital mortality in patients with ACS, the overall mortality and morbidity remains high due to missed opportunities to optimise treatment.3 The Global Registry of Acute Coronary Events (GRACE) conducted in centres in Belgium and the United Kingdom (UK) shows a long-term signal of recurrent events, such that in-hospital mortality was 3%, 4% and 5% at five-year follow up and that mortality was 15% and 18% for Belgium and UK patients, respectively.4 The GRACE study showed that patients with a higher GRACE score were at higher risk compared to low and moderate scores, and 68%, 86% and 97% deaths occurred in patients with ST-elevation myocardial infarction (STEMI), ACS and unstable angina, respectively, after initial hospital discharge. Patients with non-ST segment elevated myocardial infarction (NSTEMI) were found to have poor prognosis at six-month follow up, compared to STEMI patients, which was most likely due to patients being on less-than-optimal treatment. Medication compliance among patients is highest in the first month after ACS and Cheng et al., reported that from patients discharged on aspirin, beta blocker and statins, 34% patients had stopped at least one medicine and 12% had stopped all three medications a month after ACS.5 Only 40–45% patients were adherent with beta blocker or statins one to two years following ACS.

| Full text

October 2022 Br J Cardiol 2022;29:125–6 doi:10.5837/bjc.2022.031

Hospital–pharma clinic partnerships: a bridge too far?

Rani Khatib

Abstract

Some healthcare professionals may see the idea of ‘joint working’ between NHS Trusts and pharmaceutical companies as anathema – a bridge too far in the direction of private interests perhaps? However, when the needs of patients, the health system and the company are aligned, it can bring significant benefits for everyone.

At the Leeds Teaching Hospitals NHS Trust (LTHT), we have recently entered into a joint working partnership with Boehringer Ingelheim.1 This arrangement is helping us to develop a patient-centred clinic specifically focused on reducing cardiovascular (CV) risk in individuals with diabetes recently discharged from LTHT following a myocardial infarction (MI). Initiated in September 2021, the clinic is run jointly by the cardiology department at Leeds General Infirmary and the diabetes services at the Trust. It is shared funded by the Trust and by Boehringer Ingelheim.

| Full text

August 2022 Br J Cardiol 2022;29:127–8 doi:10.5837/bjc.2022.028

Nutrition training for medical professionals: where do we begin?

Iain Broadley, Rachel White, Ally Jaffee

Abstract

Nutrition is underrepresented in the medical curriculum; this has always been the case, but recently there has been a focus on trying to change this. A ‘call for action’ by the independent organisation Nutritank CIC and the Nutrition Implementation Coalition has led the way for this. New recommendations for curriculum changes have been proposed, but no mandatory changes are yet in place.

| Full text

June 2022 Br J Cardiol 2022;29:85–6 doi:10.5837/bjc.2022.022

The protracted path to untethered mechanical circulatory support: always the future or reality soon?

Jignesh K Patel

Abstract

Significant pharmacologic, interventional and surgical strategies in the management of coronary syndromes, together with evolving surgical and non-surgical innovations for valvular disease and improved care of congenital heart disease, have ensured that patients live longer and better lives. With these advancing therapies for cardiac disease, the number of patients surviving to develop end-stage heart failure continues to increase exponentially. While the heart as an organ has evolved to demonstrate remarkable resilience in the setting of disease, death from cardiovascular causes remains the most common cause of death in many parts of the world. Given the significant morbidity and mortality associated with end-stage heart failure, the last half century has been notable for a concentrated effort on developing therapies for the failing heart.

In this issue, Professor Stephen Westaby (see https://doi.org/10.5837/bjc.2022.021) provides an insightful personal perspective on a laudable life-long pursuit in the development of mechanical circulatory support with the ultimate goal of a fully implantable device. His long career has been punctuated by a number of seminal achievements, which have led to incremental improvements in a challenging area.

| Full text

May 2022 Br J Cardiol 2022;29:43–5 doi:10.5837/bjc.2022.016

Viruses, vaccines and cardiovascular effects

Anthony R Rees

Abstract

On the 31st March 2021, the German Health Ministry – on the advice of the Standing Committee on Vaccination (STIKO) – declared that the Astra Zeneca/Oxford Vaxzevria vaccine against SARS-CoV-2 (COVID-19), based on a chimpanzee adenovirus genetic scaffold, henceChAdOx1, would no longer be administered to those under the age of 60 years. In its hands were details of 31 cerebral venous sinus thrombosis (CVST) cases provided by the Paul Ehrlich Institute. These cases, of whom 19 had platelet deficiency, were seen after 2.7 million first and 767 second vaccine doses.

| Full text

March 2022 Br J Cardiol 2022;29:5–7 doi:10.5837/bjc.2022.007

Pipedreams, the pandemic and PoTS: is the post-COVID-19 era a turning point for PoTS services?

Morwenna Opie, Michaela Nuttall

Abstract

The paper by Gall et al., published in this issue (see https://doi.org/10.5837/bjc.2022.003), is timely and important; the largest case series from the UK, and among the largest globally detailing the clinical characteristics of patients affected with postural tachycardia syndrome (PoTS) developing after a COVID-19 infection. It brings empirical stature to the anecdotal reports of PoTS developing post-COVID-19. It articulates that this presents in a form indistinguishable from PoTS precipitated by other events.

| Full text

November 2021 Br J Cardiol 2021;28:125–6 doi:10.5837/bjc.2021.047

Motivational interviewing and outcomes in primary preventive cardiology

Justin Lee Mifsud, Joseph Galea

Abstract

The European guidelines on cardiovascular disease (CVD) prevention in clinical practice have focused on prevention through behaviour change by highlighting and promoting lifestyle therapies to better address the needs of individuals with a high-risk profile. Programmes using motivational interviewing are promising in encouraging lifestyle change. While motivational interviewing may support individuals to modify risk, its effectiveness remains uncertain. Here, we offer reflections on the application of motivational interviewing in preventive cardiology, areas of controversy, and glimpses of potential future lifestyle interventions using motivational interviewing to prevent CVD development.

| Full text

June 2021 Br J Cardiol 2021;28:47–8 doi:10.5837/bjc.2021.025

A National Heart Disease Strategy for Scotland: the BHF proposal to Government

David McColgan, Dennis Sandeman, Adrian J B Brady

Abstract

Heart disease remains a major cause of death and disability in Scotland, accounting for around 10,000 deaths each year.1 Ischaemic heart disease is still Scotland’s single biggest killer, responsible for 11.3% of all deaths in 2018, and accounts for 25,000 hospital admissions each year. While it is true that there have been improvements in survival from heart attacks and other acute events in Scotland over the last half century, it is also the case that significant challenges remain.

The reduction in deaths from heart attacks means that more people are living with heart disease as a long-term condition. On top of this, the population is getting older,2 and increasingly people are living with associated comorbidities, many requiring long-term support. The number of people living with cardiovascular risk factors in Scotland continues to increase, health inequalities persist and in some cases, have worsened.3

Beyond ischaemic heart disease, the incidence of conditions like heart failure,4 heart valve disease,5 and atrial fibrillation are increasing. There is also a need to consider the impact of less common, but no less important conditions, such as congenital heart disease and inherited heart conditions. Around 28,000 people in Scotland have an inherited heart condition, the most common of which is hypertrophic cardiomyopathy. Congenital heart disease is one of the most common birth defects in Scotland, affecting around one in every 150 births. Improved survival rates mean that a growing number of people are living into adulthood with congenital heart disease.

| Full text

June 2021 Br J Cardiol 2021;28:87–8 doi:10.5837/bjc.2021.028

50th anniversary of Ionescu’s pericardial heart valve concept

Sunil Ohri, Suvitesh Luthra

Abstract

“I will not lose; either I win or I learn” – Marian Ionescu, circa 1971

The pericardial heart valve concept is the remarkable legacy of a man and his genius. His single most defining contribution has changed the course of cardiac surgery over the last half a century and benefitted millions of patients worldwide. Since the initial design by Hufnagel of the ball-cage valve implanted in the descending thoracic aorta (1953) to correct a regurgitant aortic valve, nearly 150 valves have been designed and tested. None has stood the test of time as well as the pericardial valve (figure 1). Since the first successful human implant of the pericardial valve in the mitral position in 1971, 10 million of these have been implanted worldwide. Pericardial valves now constitute 80% of all implanted valves. The invention has driven a multi-billion dollar industry that today forms the backbone of the healthcare technology sector.

| Full text

April 2021 Br J Cardiol 2021;28:51–2 doi:10.5837/bjc.2021.022

Cardiorenal syndrome: a Bright idea with earlier roots

Xingping Dai, Bing Zhou, Stanley Fan, Han B Xiao

Abstract

Cardiorenal syndrome has attracted an enormous amount of attention, particularly in the last decade. A lot of research has been conducted in pathophysiology, haemodynamic manifestations, therapeutic options, and clinical outcomes.1,2 In practice, however, cardiorenal syndrome remains clinically challenging for both cardiologists and nephrologists. Cardiorenal syndrome covers a wide range of structural and functional disorders of both the heart and kidneys. Typically, the acute or chronic dysfunction in one organ induces acute or chronic dysfunction in the other. The interaction between the two organs may well be in multiple interfaces, such as haemodynamic cross-talk between the failing heart and the response of the kidneys and vice versa, alterations in neurohormonal markers, as well as inflammatory molecular characteristics.2 Much of the credit for the initial description of cardiorenal syndrome is attributed to Robert Bright who, in 1836, described the interdependent relationship between the kidney and the heart based on his observations on significant cardiac structural changes seen in patients with advanced kidney disease.3 The formal definition of cardiorenal syndrome and its classifications were established more recently,1,2,4 although uncertainty remains still. The classification appears to be attractive and easily applicable in clinical practice, but its value in aiding treatment or prevention strategy has yet to be ascertained.4

| Full text




Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now